What You Should Know:
– Health tech startup H1 announced that it has raised a $100M Series C round of funding. NY-based H1 plans to invest the funds in the expansion of its data and network, product development and hiring, with a goal to make H1 the core global healthcare network for every
medical professional and organization in the world.
The Series C round was led by Altimeter Capital, joined by new investors Goldman Sachs Asset Management and Flex Capital, with participation from existing investors IVP, Menlo Ventures, Transformation Capital, Lux Capital and LeadEdge.
Single Source of Truth for Healthcare Professionals
H1 has built the premier healthcare data network for Healthcare Providers (HCPs), searching scholarly data and medical claims data to surface the most relevant researchers or clinicians given any criteria. The company’s platform helps life sciences companies, hospitals, academic medical centers and health systems connect with providers, find clinical research, locate industry experts, and benchmark their organizations.
H1 solutions include:
– Explorer, the most comprehensive platform of HCPs ever assembled. HCPs can claim and update their profiles to use as their digital CV, connect with industry influencers, and access research, speaking and clinical trial opportunities.
– HCP Universe, the single source of truth about medical professionals globally. It enables healthcare organizations to identify and engage healthcare providers, from advisory board members to treatment specialists, digital opinion leaders and more.
– Trial Landscape, a robust global platform to understand principal investigator profiles and clinical trial sites for access expansion to therapeutic options for patients. Trial Landscape also helps healthcare organizations comply with new FDA guidelines related to physician and patient diversity in clinical trials.
– Carevoyance, the best targeting, sales enablement, and physician segmentation platform for medical device sellers.
Most recently, H1’s focus on allowing doctors to enhance their own individual profiles has further increased the depth and value of the proprietary data. Seven of the top 10 pharmaceutical companies in the world and several leading academic medical centers (Columbia, UPenn, and others) are now H1 customers. In 2021 to date, the company’s annual recurring revenue (ARR) has grown by over 250 percent as the appetite for health data continued to accelerate and the network effect took hold.
“We’ve created a flywheel that spins faster the more HCPs and industry partners engage with our platform and network,” said Ariel Katz, co-founder and CEO of H1. “No other company can match the volume and quality of global healthcare data H1 has, and as a result no one can match the insights we surface. The next phase of our growth will be focused on helping healthcare organizations harness our network for better decision making.”